---
title: "Claseprubart (DNTH103) in Generalized myasthenia gravis: Incidence"
description: "Formulary evidence on Claseprubart (DNTH103) in Generalized myasthenia gravis: Incidence. Topics: United States, 2021 claims and electronic health records: incidence of all myasthenia gravis; United States, 2017 commercial, Medicare, and Medicaid claims: incidence of all myasthenia gravis; United States, Medicare fee-for-service beneficiaries aged 65 years and older: incidence of all myasthenia gravis, 2008 to 2019; Taiwan, 2009 to 2019: incidence of generalized myasthenia gravis; 3 further topics. 7 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description/incidence"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-15T22:20:57-05:00"
---

# Claseprubart (DNTH103) in Generalized myasthenia gravis: Incidence

<a id="heading-2.2.1.2.1"></a>

## 2.2.1.2.1 Incidence of Generalized myasthenia gravis

<a id="topic-2.2.1.2.1-1"></a>

### United States, 2021 claims and electronic health records: incidence of all myasthenia gravis

> “Data were extracted from the Clarivate Real-World Data Repository (2016-2021), a US claims and electronic health records database.”
> “The diagnosed prevalence and incidence of MG in the United States in 2021 were calculated to be 37.0 per 100,000 persons and 3.1 per 100,000 persons, respectively.”
> “While the incidence and prevalence of MG increased with age in both men and women, higher prevalence and incidence of MG were observed in younger women (<50 years) compared with men of matching age, and in older men (≥65 years) compared with women of the same age group.”

Source: [Rodrigues et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38040629/)

<a id="topic-2.2.1.2.1-2"></a>

### United States, 2017 commercial, Medicare, and Medicaid claims: incidence of all myasthenia gravis

> “From the US commercially/Medicare-insured cohort, we calculated an age-and sex-standardized incidence of 68.5 new cases per million person-years with an adjusted prevalence of 316.4 per million.”
> “Within the Medicaid-insured population, similar yet slightly lower numbers emerged: the adjusted incidence was 49.7 new cases per million person-years, and the adjusted prevalence rate was 203.7 cases per million.”
> “We extrapolated this to calculate the overall US prevalence of 320.2 per million people and an incidence of 54 per million person-years.”

Source: [Ye et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10907989/)

<a id="topic-2.2.1.2.1-3"></a>

### United States, Medicare fee-for-service beneficiaries aged 65 years and older: incidence of all myasthenia gravis, 2008 to 2019

> “Study-eligible beneficiaries were aged 65 years and older, had at least 1 month of FFS Part A/B coverage, and were without any health maintenance organization insurance coverage.”
> “MG incidence increased from 12.2 to 13.3 per 100,000 PYs from 2008–2009 to 2018–2019 (p < 0.05).”

Source: [Bruckman et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11540456/)

<a id="topic-2.2.1.2.1-4"></a>

### Taiwan, 2009 to 2019: incidence of generalized myasthenia gravis

> “There was no temporal trend in all-cause fatality rates (range 2.76–3.79/100 patients annually) or gMG incidence rates (2.4–3.17/100,000 population annually).”
> “In 2019, the annual prevalence of gMG was 11.18 per 100,000 population and the incidence rate was 2.95 per 100,000 population.”

Source: [Herr et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10327564/)

<a id="topic-2.2.1.2.1-5"></a>

### Canada, Ontario, 2013 to 2020: incidence of all myasthenia gravis

> “Standardized incidence remained stable (3.2–4.0 per 100,000), while prevalence increased from 36 to 42 per 100,000 from 2013/14 to 2019/20.”

Source: [Barnett-Tapia et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13498700/)

<a id="topic-2.2.1.2.1-6"></a>

### Global systematic review of studies through February 2024: incidence of all myasthenia gravis

> “Incidence rates ranged from 2.3 to 61.3 cases per million person-years, with a mean incidence of 15.7 (95% CI: 11.5–19.9) and a median of 13.3 cases.”
> “Studies showed increasing rates over the years (Fig. 4): considering the period 1967–2007, the mean IR was 8.7 (95% CI: 5.5–11.9; range: 2.3–21.3) cases per million person-years, and in the period 2008–2022, the mean IR has more than doubled: 22.9 (95% CI: 14.1–31.7; range: 6.3–61.3).”
> “The American countries showed the highest mean IR cases per million person-years with a value of 23.7 (95% CI: 6.5–40.9; range: 4.7–61.3).”

Source: [Sciancalepore et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12500283/)

<a id="topic-2.2.1.2.1-7"></a>

### Global systematic review of studies from 1950 to 2007: pooled incidence of all and AChR antibody-positive myasthenia gravis

> “55 studies performed between 1950 and 2007 were included, representing 1.7 billion population-years.”
> “IR ranged from 1.7 to 21.3 cases per million person-years”
> “Pooled estimate IR (eIR) was calculated as 5.3 per million person-years (C.I.: 4.41 - 6.12).”
> “AChR MG IR ranged from 4.3 to 18.0 per million person-years with a pooled AChR MG eIR of 7.3 per million person-years (C.I.: 5.5, 7.8).”

Source: [Carr et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2905354/)

## Related pages
- [Claseprubart (DNTH103): Generalized myasthenia gravis](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Generalized myasthenia gravis](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/executive-summary.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/clinical-evidence.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/economics.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: References](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/references.md)
